Table 4.

Likelihood ratio tests of Cox regression analyses for other EORTC QLQ‐C30 scales

Variable	Total,a n = 6,895	Colon cancer, n = 1,487	Rectal cancer, n = 960	Melanoma, n = 222	Basal or squamous cell cancer, n = 614	Endometrial cancer, n = 140	Ovarian cancer,a n = 344	Prostate cancer,a n = 1,097	Thyroid cancer, n = 285	Hodgkin lymphoma,a n = 197	Non‐ Hodgkin lymphoma,a n = 1,051	Chronic lymphocytic leukemia,a n = 272	Multiple myeloma,a n = 226
Unadjusted Cox regression, −2 Log likelihood ratio
EORTC QLQ‐C30 summary score
Full model	21,207.7	4,087.3	2,543.5	42.0	267.4	232.1	1,052.5	1,807.1	223.0	182.6	3,146.3	769.6	1,263.5
Null model	21,504.1*	4,147.2*	2,586.9*	42.9	276.6*	232.2	1,076.6*	1,852.6*	227.7	182.7	3,175.3*	774.3	1,268.6
Global QOL
Full model	19,928.5	3,862.0	2,409.9	27.7	222.0	172.1	928.4	1,637.6	169.6	131.8	2,869.8	673.4	1,162.1
Null model	20,840.4*	4,085.0*	2,582.3*	42.6	262.5*	230.5*	1,012.1*	1,784.4*	227.4*	182.4*	3,014.1*	733.6*	1,194.6*
Physical functioning
Full model	20,956.3	4,037.2	2,512.1	42.8	254.8	232.2	1,054.9	1,770.4	215.3	180.8	3,121.0	741.9	1,247.8
Null model	21,453.6*	4,147.2*	2,586.9*	42.9	263.7*	232.2	1,076.6*	1,852.1*	227.7*	182.7	3,174.8*	763.7*	1,256.9*
Adjusted Cox regression b , −2 Log likelihood ratio
EORTC QLQ‐C30 summary score
Full model	20,073.7	3,874.8	2,419.1	27.0	239.7	172.0	934.2	1,636.8	168.5	136.2	2,895.3	675.9	1,204.4
Null model	20,987.7*	4,086.3*	2,583.4*	42.6	275.7*	230.5*	1,022.8*	1,784.8*	227.4*	182.5*	3,039.5*	740.9*	1,235.8*
Global QOL
Full model	19,928.5	3,862.0	2,409.9	27.7	222.0	172.1	928.4	1,637.6	169.6	131.8	2,869.8	673.4	1,162.1
Null model	20,840.4*	4,085.0*	2,582.3*	42.6	262.5*	230.5*	1,012.1*	1,784.4*	227.4*	182.4*	3,014.1*	733.6*	1,194.6*
Physical functioning
Full model	19,977.3	3,857.4	2,406.9	27.0	225.9	169.1	933.9	1,623.4	168.7	136.9	2,889.0	667.9	1,190.8
Null model	20,953.5*	4,086.3*	2,583.4*	42.6	262.8*	230.5*	1,022.8*	1,784.4*	227.4*	182.5*	3,039.0*	740.9*	1,224.2*

Likelihood ratio test is significant at p < .01. * = p < .01. Boldface = statistically significant.

^aAnalyses included multiple studies and cohorts and were therefore cluster adjusted for study.

^bAdjusted for covariates: age, sex, disease stage, treatments received, number of comorbid conditions, partner, educational level, employment status.

Abbreviations: QOL, quality of life; EORTC QLQ‐C30, European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire‐Core 30.